coetifs
10-27-2022, 07:18 PM
Having said that, I also think that we re at a point in the adjuvant therapy of many women with breast cancer, where the results are extremely good, and that it may be hard for us to improve on them in a meaningful way, and that one thing we might wish to do then is to see whether or not we can refine the way we give that therapy so that we can tailor it, so we can optimize it, and it is a rational question to ask whether or not shorter durations of an aromatase inhibitor would be as effective as a longer duration of an aromatase inhibitor in women stromectol ebay ([Only registered and activated users can see links])